Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

about

Comparison of miRNA and gene expression profiles between metastatic and primary prostate cancer.

P2860

Q45837542-070A9552-6034-4D14-AE06-7A668FFACA0D

P2860

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

Item

http://www.wikidata.org/entity/Q38912469

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

@en

type

Item

label

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

@en

prefLabel

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

@en

P1476

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

@en

P2093

Sanjay Rajagopalan

http://www.w3.org/2001/XMLSchema#string

Saumya Kankanala

http://www.w3.org/2001/XMLSchema#string

P2860

Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.

Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans.

Increase of CD26/dipeptidyl peptidase IV expression on human gingival fibroblasts upon stimulation with cytokines and bacterial components.

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression.

P304

484-492

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOL.0000000000000340

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jixin Zhong

P577

2016-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27472408

http://www.w3.org/2001/XMLSchema#string

P932

5147592

http://www.w3.org/2001/XMLSchema#string

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

about

P2860

P2860

Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932